REGN Jan 2025 650.000 call
| Previous close | 222.16 |
| Open | 222.16 |
| Bid | 274.30 |
| Ask | 281.80 |
| Strike | 650.00 |
| Expiry date | 2025-01-17 |
| Day's range | 222.16 - 222.16 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Insider MonkeyJim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful
We recently published a list of Jim Cramer’s Must-Watch List: 10 Stocks to Look After. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other Jim Cramer’s must-watch stocks. In a recent episode of Mad Money, Jim Cramer explained that with the economy slowing down, the Federal […]
ZacksRegeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
GlobeNewswireDupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the
